Varying the temperature and insertion time of the liquid determines the depth of the frozen layer. The first application is envisioned to be the treatment of abnormal uterine bleeding, a common condition that is not easily treated and often requires radical surgery. Prior to this discovery there was no diagnostic test for CFS and physicians had to rely solely on a combination of clinical symptoms, each of which can also be due to other disease conditions. The company started commercial testing of clinical samples for the new protein in 1998, and is in the process of developing a diagnostic kit for sale worldwide. The company moved operations in 2000 to its own newly constructed building, which includes greatly expanded research facilities.
Clinical trials are underway in several European countries, as well as in Australia and New Zealand.